High risk of drug-resistant tuberculosis when first-line therapy fails in a high HIV prevalence setting

International Journal of Tuberculosis and Lung Disease

Volumn 17, Issue 1, 2013, Pages

  Satti, Hind ^a,b   McLaughlin, M M ^a,c   Seung, K J ^a,c   Becerra, M C ^a,b,c   Keshavjee, S ^a,b,c  

^a PARTNERS IN HEALTH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Drug resistance; HIV AIDS; Multidrug resistant tuberculosis; Treatment failure

Indexed keywords

ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEALTH PROGRAM; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT FAILURE;

ADULT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; LESOTHO; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT FAILURE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84871246681     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.12.0344     Document Type: Article

References (36)

1. World Health Organization. Treatment of tuberculosis: guidelines. 4th ed. WHO/HTM/TB/2009.420. Geneva, Switzerland: WHO, 2010.
2. Menzies D, Benedetti A, Paydar A, et al. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med 2009; 6: e1000150.
3. Mak A, Thomas A, del Granado M, Zaleskis R, Mouzafarova N, Menzies D. Influence of multidrug resistance on tuberculosis treatment outcomes with standardized regimens. Am J Respir Crit Care Med 2008; 178: 306-312.
4. Ottmani S-E, Zignol M, Bencheikh N, Laâsri L, Chaouki N, Mahjour J. Results of cohort analysis by category of tuberculosis retreatment cases in Morocco from 1996 to 2003. Int J Tuberc Lung Dis 2006; 10: 1367-1372. (Pubitemid 44924591)
5. Espinal M A. Time to abandon the standard retreatment regimen with first-line drugs for failures of standard treatment. Int J Tuberc Lung Dis 2003; 7: 607-608. (Pubitemid 36806852)
6. World Health Organization. Global tuberculosis control 2011. WHO/HTM/TB/2011.16. Geneva, Switzerland: WHO, 2011.
7. Centers for Disease Control and Prevention. Treatment of tuberculosis: American Thoracic Society, CDC, Infectious Diseases Society of America. MMWR 2003; 52 (RR-11): 1-80.
8. Partners In Health. The PIH guide to the medical management of multidrug-resistant tuberculosis. Boston, MA, USA: Partners In Health, 2003.
9. Mukherjee J S, Rich M L, Socci A R, et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 2004; 363: 474-481. (Pubitemid 38210067)
10. Tuberculosis Coalition for Technical Assistance. International Standards for Tuberculosis Care (ISTC). 2nd ed. The Hague, The Netherlands: Tuberculosis Coalition for Technical Assistance, 2009.
11. He G X, Xie Y G, Wang L X, et al. Follow-up of patients with multidrug-resistant tuberculosis four years after standardized first-line drug treatment. PLoS ONE 2010; 5: e10799.
12. Espinal M A, Kim S J, Suarez P G, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000; 283: 2537-2545. (Pubitemid 30324196)
13. Lan N T N, Iademarco M F, Binkin N J, Tung L B, Quy H T, Cô N V. A case series: initial outcome of persons with multidrug-resistant tuberculosis after treatment with the WHO standard retreatment regimen in Ho Chi Minh City, Vietnam. Int J Tuberc Lung Dis 2001; 5: 575-578. (Pubitemid 32587290)
14. Schreiber Y S, Herrera A F, Wilson D, et al. Tuberculosis retreatment category predicts resistance in hospitalized retreatment patients in a high HIV prevalence area. Int J Tuberc Lung Dis 2009; 13: 1274-1280.
15. Jones-Lopez E C, Ayakaka I, Levin J, et al. Effectiveness of the standard WHO recommended retreatment regimen (Category II) for tuberculosis in Kampala, Uganda: a prospective cohort study. PLoS Med 2011; 8: e1000427.
16. Matthys F, Rigouts L, Sizaire V, et al. Outcomes after chemotherapy with WHO Category II regimen in a population with high prevalence of drug resistant tuberculosis. PLoS ONE 2009; 4: e7954.
17. Saravia J C, Appleton S C, Rich M L, Sarria M, Bayona J, Becerra M C. Retreatment management strategies when firstline tuberculosis therapy fails. Int J Tuberc Lung Dis 2005; 9: 421-429. (Pubitemid 40524034)
18. Seung K J, Gelmanova I E, Peremitin G G, et al. The effect of initial drug resistance on treatment response and acquired drug resistance during standardized short-course chemotherapy for tuberculosis. Clin Infect Dis 2004; 39: 1321-1328. (Pubitemid 39458518)
19. Han L L, Sloutsky A, Canales R, et al. Acquisition of drug resistance in multidrug-resistant Mycobacterium tuberculosis during directly observed empiric retreatment with standardized regimens. Int J Tuberc Lung Dis 2005; 9: 818-821. (Pubitemid 41139138)
20. Gandhi N R, Shah N S, Andrews J R, et al. HIV co-infection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med 2010; 181: 80-86.
21. World Health Organization. Global tuberculosis control r eport 2010. WHO/HTM/TB/2010.7. Geneva, Switzerland: WHO, 2010.
22. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008. WHO/HTM/TB/2008.402. Geneva, Switzerland: WHO, 2008.
23. Seung K J, Omatayo D B, Keshavjee S, Furin J J, Farmer P E, Satti H. Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in southern Africa. PLoS ONE 2009; 4: e7186.
24. World Health Organization. Growth reference 5-19 years: BMI-for-age (5-19 years). Geneva, Switzerland: WHO, 2012. http:// www.who.int/growthref/who-2007- bmi-for-age/en/index.html Accessed November 2012.
25. Becerra M C, Freeman J, Bayona J, et al. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2000; 4: 108-114. (Pubitemid 30123642)
26. Rich M L, Socci A R, Mitnick C D, et al. Representative drug susceptibility patterns for guiding design of retreatment regimens for MDR-TB. Int J Tuberc Lung Dis 2006; 10: 290-296.
27. Velasquez G E, Yagui M, Cegielski J P, et al. Targeted drugr esistance testing strategy for multidrug-resistant tuberculosis detection, Lima, Peru, 2005-2008. Emerg Infect Dis 2011; 17: 432-440.
28. Chavez Pachas A M, Blank R, Smith Fawzi M C, Bayona J, Becerra M C, Mitnick C D. Identifying early treatment failure on Category I therapy for pulmonary tuberculosis in Lima Ciudad, Peru. Int J Tuberc Lung Dis 2004; 8: 52-58. (Pubitemid 38120706)
29. Gler M T, Macalintal L E, Raymond L, Guilatco R, Quelapio M I D, Tupasi T E. Multidrug-resistant tuberculosis among previously treated patients in the Philippines. Int J Tuberc Lung Dis 2011; 15: 652-656.
30. Quy H T W, Lan N T N, Borgdorff M W, et al. Drug resistance among failure and relapse cases of tuberculosis: is the standard re-treatment regimen adequate? Int J Tuberc Lung Dis 2003; 7: 631-636. (Pubitemid 36806857)
31. Yoshiyama T, Yanai H, Rhiengtong D, et al. Development of acquired drug resistance in recurrent tuberculosis patients with various previous treatment outcomes. Int J Tuberc Lung Dis 2004; 8: 31-38. (Pubitemid 38120703)
32. Boehme C C, Nicol M P, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011; 377: 1495-1505.
33. Pepper D J, Marais S, Wilkinson R J, et al. Clinical deterioration during antituberculosis treatment in Africa: incidence, causes and risk factors. BMC Infect Dis 2010; 10: 83.
34. Li J, Munsiff S S, Driver C R, Sackoff J. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000. Clin Infect Dis 2005; 41: 83-91. (Pubitemid 40863749)
35. Meintjes G, Lawn S, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008; 8: 516-523. (Pubitemid 352005824)
36. Mphahlele M, Syre H, Valvatne H, et al. Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates. J Clin Microbiol 2008; 46: 3459-3464.